EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

Javier Melchor iD, Marcos Garcia-Lacarte iD, Sara C Grijalba iD, Adrián Arnaiz-Leché iD, Marién Pascual iD, Carlos Panizo iD, Oscar Blanco iD, Victor Segura iD, Francisco J Novo iD, Juan Garcia Valero iD, Patricia Pérez-Galán iD, Jose A Martinez-Climent iD und 1 weitere

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2022-006113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Javier Melchor und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Immunotherapy, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Approximately one-third of diffuse large B cell lymphoma (DLBCL) patients exhibit co-expression of MYC and BCL2 (double-expressor lymphoma, DEL) and have a dismal prognosis. Targeted inhibition of the anti-apoptotic protein BCL2 with venetoclax (ABT-199) has been approved in multiple B-cell malignancies and is currently being investigated in clinical trials for DLBCL. Whether BCL2 anti-apoptotic function represents a multifaceted vulnerability for DEL-DLBCL, affecting both lymphoma B cells and T cells within the tumor microenvironment, remains to be elucidated.

Methods

Here, we present novel genetically engineered mice that preclinically recapitulate DEL-DLBCL lymphomagenesis, and evaluate their sensitivity ex vivo and in vivo to the promising combination of venetoclax with anti-CD20-based standard immunotherapy.

Results

Venetoclax treatment demonstrated specific killing of MYC + /BCL2 + lymphoma cells by licensing their intrinsically primed apoptosis, and showed previously unrecognized immunomodulatory activity by specifically enriching antigen-activated effector CD8 T cells infiltrating the tumors. Whereas DEL-DLBCL mice were refractory to venetoclax alone, inhibition of BCL2 significantly extended overall survival of mice that were simultaneously treated with a murine surrogate for anti-CD20 rituximab.

Conclusions

These results suggest that the combination of anti-CD20-based immunotherapy and BCL2 inhibition leads to cooperative immunomodulatory effects and improved preclinical responses, which may offer promising therapeutic opportunities for DEL-DLBCL patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicImmunotherapyLymphoma, Large B-Cell, DiffuseAnimalsMiceDisease Models, AnimalProto-Oncogene Proteins c-bcl-2Tumor MicroenvironmentProto-Oncogene Proteins c-mycSulfonamides

Stichwörter der Autor:innen

B-lymphocytesCD4-CD8 ratiodrug evaluation, preclinicalhematologic neoplasmsimmunotherapy

Substanzen

Bridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycvenetoclaxSulfonamides

Autor:innen und Institutionen

  • Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, Spain.
  • Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.
  • Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  • Department of Hematology, Clinica Universidad de Navarra, Pamplona, Spain.
  • Current address: Department of Hematology and Hemotherapy, Hospital Universitario Donostia, San Sebastián, Spain.
  • Department of Pathology, Universidad de Salamanca, Salamanca, Spain.

ORCID-Profile: Javier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco J Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose A Martinez-Climent, Sergio Roa

Zitieren

APA

Melchor, J., Garcia-Lacarte, M., Grijalba, S. C., Arnaiz-Leché, A., Pascual, M., Panizo, C., Blanco, O., Segura, V., Novo, F. J., Valero, J. G., Pérez-Galán, P., Martinez-Climent, J. A., & Roa, S. (2023). Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006113

Vancouver

Melchor J, Garcia-Lacarte M, Grijalba SC, Arnaiz-Leché A, Pascual M, Panizo C, et al. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006113

BibTeX
@article{Melchor2023,
  author = {Melchor, Javier and Garcia-Lacarte, Marcos and Grijalba, Sara C and Arnaiz-Leché, Adrián and Pascual, Marién and Panizo, Carlos and Blanco, Oscar and Segura, Victor and Novo, Francisco J and Valero, Juan Garcia and Pérez-Galán, Patricia and Martinez-Climent, Jose A and Roa, Sergio},
  title = {Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2022-006113}
}
Kostenlos starten →